Zenas BioPharma Eyes Commercial Stage with Key Drug and $250M in Funding

WALTHAM, Mass. – March 16, 2026 – Zenas BioPharma has signaled a significant pivot from a clinical-stage developer to a potential commercial powerhouse, detailing plans to submit its lead autoimmune drug, obexelimab, for regulatory approval while securing up to $250 million in new financing. The company's fourth-quarter and full-year 2025 financial report, released today, paints a picture of a biopharmaceutical firm rapidly maturing, with a broad pipeline advancing alongside preparations for its first market entry.

The update confirms that Zenas is on track for major regulatory milestones following highly positive late-stage trial results. This transition is bolstered by a substantial non-dilutive debt facility from life sciences investment firm Pharmakon, providing critical capital to fuel commercialization efforts and continued research without immediately diluting shareholder value.

“Following the highly positive Phase 3 INDIGO results reported earlier this year, we enter 2026 with strong momentum as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. “This partnership [with Pharmakon] strengthens our balance sheet and provides us with the financial flexibility to commercialize obexelimab while investing in our broader pipeline.”

A Pivotal Year for Obexelimab

The centerpiece of Zenas's near-term strategy is obexelimab, an innovative antibody targeting the root cause of several autoimmune diseases. The company announced its intention to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD). A similar application to the European Medicines Agency (EMA) is expected in the second half of the year.

This move follows the success of the Phase 3 INDIGO trial, which demonstrated that obexelimab achieved a highly statistically significant 56% reduction in the risk of disease flare compared to a placebo. IgG4-RD is a chronic, fibro-inflammatory condition that can cause tumor-like masses and irreversible damage to multiple organs, including the pancreas, bile ducts, and kidneys. The current standard of care often involves long-term use of steroids, which carry a heavy burden of side effects.

Obexelimab’s unique mechanism offers a key point of differentiation. Unlike therapies that deplete B cells, obexelimab is a bifunctional antibody that binds to both CD19 and FcγRIIb on B cells. This dual engagement inhibits the cells' activity—stopping them from producing harmful autoantibodies and driving inflammation—without eliminating them entirely. This novel, non-depleting approach could offer a more modulated and potentially safer long-term treatment profile. The drug's potential for self-administered subcutaneous injection also promises greater convenience for patients managing this chronic illness.

Beyond IgG4-RD, Zenas anticipates topline results in the fourth quarter of 2026 from its Phase 2 SunStone trial evaluating obexelimab in Systemic Lupus Erythematosus (SLE), another complex autoimmune disease with significant unmet needs.

Fortifying the Financial Future

Supporting this ambitious clinical and commercial agenda is a newly secured five-year, up to $250 million senior secured debt facility from Pharmakon Advisors. This non-dilutive financing is a strategic coup, providing substantial capital while protecting existing shareholders from the dilution that an equity offering would cause. The first $75 million was issued at closing, with the remaining tranches available contingent on achieving key regulatory and commercial milestones for obexelimab.

This financial injection is crucial, as the company’s 2025 financial results reflect a period of intense investment. Zenas reported a net loss of $377.7 million for the year, a significant increase from $157.0 million in 2024. However, a substantial portion of this loss—$171.7 million—is attributed to acquired in-process research and development (AIPR&D). This one-time accounting charge primarily relates to the strategic acquisition of its multiple sclerosis and IL-17 inhibitor programs, representing an investment in future growth rather than a recurring operational expense.

With $360.5 million in cash and investments as of year-end 2025, combined with the new debt facility, Zenas projects a cash runway sufficient to fund operations into the second quarter of 2027. This runway could extend into the fourth quarter of 2027, assuming receipt of further milestone-based payments, giving the company a solid financial foundation as it navigates the costly path to commercialization.

Deepening the Pipeline in High-Need Areas

While obexelimab is the immediate focus, Zenas is simultaneously advancing a multi-front attack on autoimmune diseases. The company is making significant strides with orelabrutinib, a highly selective, oral Bruton’s Tyrosine Kinase (BTK) inhibitor designed to penetrate the central nervous system.

A global Phase 3 trial of orelabrutinib in Primary Progressive Multiple Sclerosis (PPMS) is already underway. PPMS is a debilitating form of MS with very few approved treatments. Furthermore, Zenas plans to initiate another Phase 3 trial in the first quarter of 2026 for non-active Secondary Progressive MS (naSPMS), another area of high unmet medical need. By targeting progressive forms of MS, Zenas is positioning orelabrutinib to potentially address the core neurodegenerative aspects of the disease.

The company is also cultivating its next generation of therapies. Progress is being made on ZB014, a half-life extended version of an anti-CD19 antibody that could offer a less frequent, once-monthly dosing schedule. Meanwhile, its oral IL-17 inhibitor, ZB021, is expected to enter Phase 1 trials in the second quarter of 2026, with initial data anticipated by year-end. This molecule could offer a convenient oral alternative to injectable drugs for a range of rheumatic and dermatologic diseases. With these assets, Zenas is building a durable franchise aimed at transforming patient care across a spectrum of immune-mediated conditions.